Last reviewed · How we verify
SP-8203
SP-8203 is a small molecule that targets the SGLT2 receptor.
SP-8203 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | SP-8203 |
|---|---|
| Also known as | SP8203HCL, Otaplimastat (SP-8203) |
| Sponsor | Shin Poong Pharmaceutical Co. Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, SP-8203 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care (PHASE3)
- Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (PHASE2)
- Safety, Tolerability and Pharmacokinetics of SP-8203 (PHASE1)
- Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP-8203 CI brief — competitive landscape report
- SP-8203 updates RSS · CI watch RSS
- Shin Poong Pharmaceutical Co. Ltd. portfolio CI